Interventional Cardiology

COVID-19 Response

Medtronic is supporting a public health campaign — led by the American Heart Association and the American Stroke Association — urging the public to seek emergency care when they need it. See what else we're doing in the fight against COVID-19.

Visit the Resource Center
Close-up of female physicians with protective gear on during Covid-19

Product and Therapy Innovation

VenaSeal closure system on gray gradient background

Innovations to the VenaSeal Closure System

Nonthermal cyanoacrylate ablation for treatment of superficial venous disease. The VenaSeal closure system is safe and effective and backed by long-term data.1-4 Plus, simple innovations and new techniques mean greater* impact for you and your practice.

*All statements of being “greater” are as compared to previous version and procedure technique.

Abre venous self-expanding stent system on a gray gradient background

Treating Deep Venous Disease with a Dedicated Stent

The Abre™ venous self-expanding stent system is designed for the unique challenges of venous disease. It offers easy deployment, to let physicians focus on their patient, and delivers demonstrated endurance, to give patients freedom of movement.5,6

Close-up view of the cusp overlap technique with TAVR within human anatomy

CUSP Overlap Technique with Evolut TAVR

The cusp overlap technique brings precision and control to the TAVR procedure by isolating the non-coronary cusp, providing an accurate anatomical view to access and achieve the target implant depth. In combination with slow deployment starting at the supra-annular level, the valve is able to descend to its target position with minimal catheter manipulation, minimizing the risk of interaction with the conduction system.

Close-up illustration of the Endurant AAA stent graft sac regression within human anatomy

Addressing Sac Regression Factors

Endurant AAA stent graft demonstrates consistent and high sac regression rates across straightforward and complex anatomies.7,8 With:

  • Accurate placement and controlled deployment8
  • Continuous seal, fixation, and graft conformability8
  • Durable hemostatic barrier and resistance against type II endoleaks9
Resolute Onyx drug-eluting stent on a blue gradient background

Evidence Counts for Short DAPT Decisions

The Onyx ONE Clear Analysis evaluated over 1,500 complex high bleeding risk (HBR) patients, which led Resolute Onyx™ DES to receive an indication for HBR patients and 1-month DAPT labeling.10

Illustration representing a Resolute Onyx DES 4.50 or 5.00 mm size expanding to a maximum inner diameter of 6.00 mm

Greater Expansion Capabilities for 
Resolute Onyx DES

Resolute Onyx DES now offers greater expansion capabilities to treat vessel sizes from 2.00–5.00 mm, with the ability to expand XLV sizes up to 6.00 mm.10

Clinical Evidence

12-Month Results from the Abre Clinical Study

The ABRE clinical study demonstrates the safety and effectiveness of the Abre venous stent.5 Learn more about the study and the 12-month results.

Sustained Effectiveness through 24 Months for AV Restenosis1

The IN.PACT AV drug-coated balloon is the FIRST AND ONLY DCB to show superior and sustained results through two years in treating AV fistula lesions, compared to PTA.11,12

Evolut TAVR Hemodynamic Data

The Evolut TAV's supra-annular, self-expanding valve design delivers exceptional hemodynamics and is the only TAVR device to demonstrate hemodynamic superiority in a low-risk clinical trial versus SAVR at one year.13

Onyx One Clear Analysis Results Now Published

Read the Circulation: Cardiovascular Interventions article, evaluating Resolute Onyx DES in ~1,500 highly complex HBR patients on 1-month DAPT.

Currently Enrolling Patients:
SPYRAL DYSTAL Study

Designed to evaluate if a targeted procedural approach in the distal main and first order branches provides similar BP reductions as those observed in the SPYRAL HTN-OFF MED Pivotal Trial. Learn more at clinicaltrials.gov.

Contact us to learn more and discuss patient eligibility requirements for SPYRAL HTN-ON MED or SPYRAL DYSTAL trials.

Currently Enrolling Patients:
SPYRAL HTN-ON MED Trial

Designed to determine the safety and efficacy of renal denervation (RDN) in the presence of up to three standard antihypertensive medications. Learn more at clinicaltrials.gov.

CAUTION: Investigational device. Limited by federal (U.S.) law to investigational use.

Education and Training

New, Expert-led CTO PCI Course Modules

Browse CTO PCI course modules, including physician-narrated videos now available on Medtronic Academy. Log in to start the courses or bookmark for later.

TAVR Global Grand Rounds

Access interactive global webcasts delivered by industry-leading experts on a wide range of relevant topics related to transcatheter aortic valve replacement. 

DAPT Considerations in HBR Patients

Watch as subject matter experts review case studies and discuss the most recent clinical evidence, as well as decision-making for complex HBR patients, like those studied in the Onyx ONE Month DAPT Program.

Building Success in CTO PCI Webinar Series

Watch the full, four-part webinar series, “Building Success in CTO PCI — What Would You Do?” including the final segment featuring Dr. Pershad, Dr. Brilakis, Dr. Maran, and Dr. Yeh.

Aortic Virtual Education

As your partner in the evolving healthcare landscape, we've developed various webinar series for real-time and on-demand learning with peer-to-peer discussion.

Medtronic Academy

Visit Medtronic Academy

Connect with Us    

Additional Resources

References

1

Morrison N, Gibson K, Vasquez M, et al. Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. March 2020;8(6):978-989.

2

Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. April 2015;61(4):985-994.

3

Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European Multicenter Cohort Study on Cyanoacrylate Embolization for treatment of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. March 2021;9(2):329-334.

4

Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Thirty-sixth-month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. September 2017;5(5):658-666.

5

ABRE CSR v1.2 30/JUL/2020.

6

Test data on file at Medtronic. Bench test results may not be indicative of clinical performance.

7

Bӧckler D, Li C, Dansey K, et al. Sac regression is associated with lower all-cause mortality after contemporary endovascular aneurysm repair — a new paradigm for success. Presented online at ESVS 34th Annual Meeting, October 6, 2020.

8

Medtronic data on file.

9

Wakefield TW, Shulkin BL, Fellows EP, Petry NA, Spaulding SA, Stanley JC. Platelet reactivity in human aortic grafts: a prospective, randomized midterm study of platelet adherence and release products in Dacron and polytetrafluoroethylene conduits. J Vasc Surg. February 1989;9(2):234-243.

10

Resolute Onyx DES IFU.

11

Holden A. Presented at Charing Cross 2021.

12

Trerotola SO, Saad TF, Roy-Chaudhury P. Lutonix AV Clinical Trial Investigators. The Lutonix AV Randomized Trial of Paclitaxel-Coated Balloons in Arteriovenous Fistula Stenosis: 2-Year Results and Subgroup Analysis. J Vasc Interv Radiol. January 2020;31(1):1-14.e5. 

13

Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.